Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company’s web site at www.adherex.com.
- 17 years ago
QualityStocks
Adherex Technologies, Inc. (AMEX: ADH)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – RedCloud Holdings plc (NASDAQ: RCT) to Participate in ROTH 15th Annual London Conference
RedCloud Holdings (NASDAQ: RCT) announced that CEO and Co-Founder Justin Floyd will attend the ROTH…
-
ONAR Holding Corp. (ONAR) Takes the Lead in AI-Driven Marketing as CEO Shares Vision
ONAR’s core focus is to accelerate revenue for middle-market companies via AI technology, innovation and…
-
FAVO Capital Inc. (FAVO): Aligning for Growth in a Booming Alternative Lending Market
FAVO recently secured an $8 million equity investment to fund growth and accelerate its plan…